hrvatski

Metotreksat – zlatni standard u reumatologiji

Methotrexate (MTX) is a structural analogue of folic acid which is used primarily to treat inMammatory rheumatic diseases, with oral or parenteral administration. The efficacy of MTX in the treatment of rheumatoid arthritis has been demonstrated in several randomized clinical studies and conformed in meta-analyses. Today, MTX represents the golden standard for the treatment of rheumatoid arthritis. The treatment starts at doses between 7.5 and 15 mg per week, with possible dose escalation based on disease activity. Careful patient monitoring reduces the risk of hepatotoxicity and other adverse effects, making MTX the drug of first choice for the treatment of rheumatoid and psoriatic arthritis.

metotreksat ; reumatoidni artritis ; psorijatični artritis

nije evidentirano